Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 5, 1998, Pages 492-498

  Piscitelli, Stephen C ^a   Forrest, Alan ^b   Vogel, Susan ^b   Chaitt, Doreen ^b   Metcalf, Julia ^b   Stevens, Randy ^b   Baseler, Michael ^b   Davey, Richard T ^b   Kovacs, Joseph A ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031741466     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90132-1     Document Type: Article

References (26)

1. Piscitelli SC, Minor JR, Saville MW, Davey Jr RT. Immune based therapies for treatment of HIV infection. Ann Pharmacother 1996;30:62-76.
2. Rook AH, Hooks JJ, Quinnan GV, Lane HC, Maischewitz JF, Macher AM, et al. Interleukin-2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a γ-interferon-dependent mechanism. J Immunol 1985;134:1503-7.
3. Rook AH, Masur H, Lane HC, Frederick W, Kasahara T, Macher AM, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immunodeficiency syndrome. J Clin Invest 1983;72:398-403.
4. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker R, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-6.
5. Davey RT Jr, Chaitt DG, Piscitelli SC, Wells MJ, Kovacs JA, Walker R, et al. Subcutaneous administration of interleukin-2 in HIV-1 infected individuals. J Infect Dis 1997;175:781-9.
6. Davey RT, Chaitt D, Kovacs J, Walker R, Polis M, Falloon J, et al. Subcutaneous interleukin-2 therapy is capable of inducing marked sustained increases in CD4 counts in early HIV-infected patients. Xlth International Conference on AIDS, Vancouver, BC, July 1996.
7. Konrad MW, Hemstreet G, Hersh EM, Mansell PWA, Mertelsmann R, Kolitz JE, et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 1990;50:2009-17.
8. Pais RC, Ingrim NB, Garcia ML, Abdel-Mageed A, McKolanis J, Ingrim ME, et al. Pharmacokinetics of recombinant interleukin-2 in children with malignancies: a pediatric oncology group study. J Biol Response Mod 1990;9:517-21.
9. Schwartz DH, Merigan TC. Interleukin-2 in the treatment of HIV disease. Biotherapy 1990;2:119-36.
10. Whittington R, Faulds D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-514.
11. Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, Rosenberg SA. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1987;47:2188-95.
12. Lotze MT, Matory YL, Ettinghausen SE, Raymer AA, Sharrow SO, Seipp CAY, et al. In vivo administration of purified human interleukin-2; II: half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985; 135:2865-75.
13. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J AIDS 1991;4:11-23.
14. Piscitelli SC, Reiss WG, Figg WD, Petros WP. Pharmacokinetic studies with recombinant cytokines: scientific issues and practical considerations. Clin Pharmacokinet 1997;32:368-81.
15. Piscitelli SC, Wells MJ, Metcalf JA, Baseler M, Stevens RA, Davey Jr RT. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. Pharmacotherapy 1996;16:754-9.
16. Steimer JL, Mallet J, Golmard J, Boisieux J. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed effects model. Drug Metab Rev 1984;15:265-97.
17. D'Argenio DZ, Schumitzky A. ADAPTII user's guide. Los Angeles: Biomedical Simulations Resource, University of Southern California; 1990.
18. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115-34.
19. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6: 165-75.
20. Lotze MT, Rosenberg SA. Interleukin-2 as pharmacologic reagent. In: Smith KA, editor. Interleukin-2. San Diego: Academic Press; 1988.
21. Kearns CM, Wang WC, Stute N, Ihle JN, Evans WE. Disposition of recombinant human granulocyte colony stimulating factor in children with severe recombinant neutropenia. J Pediatr 1993;123:471-9.
22. Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989;74:1303-7.
23. Petros WP, Rabinowitz J, Stuart AR, Gilbert CJ, Kanakura Y, Griffin JD, et al. Disposition of recombinant human granulocyte-macrophage colony stimulating factor in patients receiving high dose chemotherapy and autologous bone marrow support. Blood 1992;80:1135-40.
24. Bukowski RM, Budd GT, Gibbons JA, Bauer RJ, Childs A, Antal J, et al. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 1994;12:97-106.
25. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76: 1718-22.
26. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-19.